{"name":"Shanghai Proton and Heavy Ion Center","slug":"shanghai-proton-and-heavy-ion-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Conventional chemotherapy","genericName":"Conventional chemotherapy","slug":"conventional-chemotherapy","indication":"Other","status":"marketed"},{"name":"Maintenance chemotherapy 2","genericName":"Maintenance chemotherapy 2","slug":"maintenance-chemotherapy-2","indication":"Maintenance therapy following induction chemotherapy in various malignancies (specific indication not specified)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Maintenance chemotherapy 1","genericName":"Maintenance chemotherapy 1","slug":"maintenance-chemotherapy-1","indication":"Cancer maintenance therapy (specific indication dependent on primary malignancy and induction regimen)","status":"phase_3"}]}],"pipeline":[{"name":"Conventional chemotherapy","genericName":"Conventional chemotherapy","slug":"conventional-chemotherapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Maintenance chemotherapy 1","genericName":"Maintenance chemotherapy 1","slug":"maintenance-chemotherapy-1","phase":"phase_3","mechanism":"Maintenance chemotherapy 1 refers to a continuation of cytotoxic chemotherapy after initial induction treatment to sustain disease control and improve long-term outcomes.","indications":["Cancer maintenance therapy (specific indication dependent on primary malignancy and induction regimen)"],"catalyst":""},{"name":"Maintenance chemotherapy 2","genericName":"Maintenance chemotherapy 2","slug":"maintenance-chemotherapy-2","phase":"phase_3","mechanism":"Maintenance chemotherapy 2 refers to a continuation of cytotoxic chemotherapy after initial induction therapy to sustain disease control and improve long-term outcomes.","indications":["Maintenance therapy following induction chemotherapy in various malignancies (specific indication not specified)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPZFBfM2x3cm5ESUFSZ0I0UWVlMkJzNEdTTWduZzIxYm1QOVhUc3VmenEwLXZmTUg4NURXamowR0tJSF9xM213ZTNmTWd1eTNfQk5rSTd4OUhHdnlob21NdGIxNHdDbk1oQ0ZVdnZtUW9IQ1VQRlFSNHI0YzFYYUF3anhZV20zRTBOYXlzZGM0U0ZWak1qVmdpVkRXQmhWSGpFbGJYdTJ2QVl6bVM2a2RNMHVpLWJNMEhBNk5WRmgtaE5ON3NadUMxUnJ6Q0U?oc=5","date":"2024-09-26","type":"pipeline","source":"citynewsservice.cn","summary":"High-end children's hospital to focus on blood disease and cancer - citynewsservice.cn","headline":"High-end children's hospital to focus on blood disease and cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOSmpmdzMxVE5YTy1MSFcxV0s2TDNuOUtPY1lGWk13UmhJdGJfcl95NVJUVUJfb0RocUVHeFNLaUVMZ3lMMTMwX1dEMDVtQVBkZl9WYlpkajBGdU9rOVlFWTd5MWVUNlVEdDRFMGpMZTlsRjYxMkNxdS1KcFhKN3ZCZmdCVWVUUGFleHFLWFNNc0FYbkhGSUNEOUE3WDIwVEh6TERzUkEwZUpsR2YzSlJz?oc=5","date":"2024-06-26","type":"pipeline","source":"Frontiers","summary":"Editorial: Novel biomaterials to improve the biological effects of electromagnetic and particle radiation - Frontiers","headline":"Editorial: Novel biomaterials to improve the biological effects of electromagnetic and particle radiation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQb3pkOHBkb3pQbmp5OWc2NU1ZQmdYbkJCVGpWVGp0a1NYV0p5T3pSd1ZfUG9wNnJfWG85Ums1VnF6clZ6bXBZcWFHNEN3d215M0t2VVQ0RmtSZkFlUlpOYVpMaUxrNTJzRmY5bzRNX3VfVWp0MlBnLW9UOXJtUGdSMEFQb0FKQlphY3Rmb0FNSkJzZw?oc=5","date":"2021-05-10","type":"pipeline","source":"Physics World","summary":"PET/CT scans verify dose delivered during carbon-ion therapy - Physics World","headline":"PET/CT scans verify dose delivered during carbon-ion therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNOVc0UXdQR0RvVTZRRk4ycUphU293Q1dVU3h3ek5YZElNVmhPNWtXcDlUc2taNDRNeVdxQXdjTDQ0ZEJ1dUYyWkNlcENqMUtINGY5OG9RdUpYNGwySnVEUmdVRUhlMVV6NEdFYjFRSzUwWFNwWndkdVg0TW55bDdrd1NMLURIajlCeFJtUnJheXowNnFqNkNjb3hySjJpNTZuUlVyY2pMdzRrZ3p1dFhjRmhsOA?oc=5","date":"2019-12-24","type":"pipeline","source":"dovepress.com","summary":"CMAR - dovepress.com","headline":"CMAR","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}